Case File
efta-02702243DOJ Data Set 11OtherEFTA02702243
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02702243
Pages
4
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Barrett, Paul S
Sent:
Tuesday, October 2, 2012 5:22 PM
To:
'Epstein, Jeffrey (jeevacation@qmaiLcomy
Cc:
Giuffrida, David J; Ens, Amanda
Subject:
To Do -
Attachments:
ipayment OW init.pdf
Jeffrey
=span style="font-size:11.0pt;font-family:"Calibri","san=-serir;color:elF497D">For Haze, we have $5MM in the JPM
High Yield B=nd Fund. The SEC yield on that fund has come down to 5.60%. I think =e should sell $1.5MM of that
position and:
<=p>
Buy $1MM of the Kindr=d Healthcare bond from yesterday (ytm 8.25%)
=p class="MsoListParagraph" style="text-indent:-.25in;mso-list:I3 lev=ll Ifo7">-=nbsp;
<=span>Buy $500K of the
iPayment 10=2E25% 2018 (yield 12.70%)
Let me know</=>
Paul=o:p>
</=>
• =nbsp;
iPayment, Inc. provides financial transaction processi=g services. The company's payment processing
services enable merchants=to accept credit cards, debit cards, checks, and gift cards as forms=of payment for swipe
transactions as well as card-not-present transactions=that are conducted over the internet or phone. The Company
offers credit=and debit card-based payment processing services, including, card authoriz=tion, data capture, settlement,
merchant accounting, risk management= fraud detection, merchant assistance, support, and charge-back services=2E
iPayment serves merchants throughout the United States.
<=pan style="font-size:11.0ptfont-family:"Calibri","sans=serif"">
•
=OD The company focuses on =mall businesses, which results in a higher failure rate, but acquiring new=customers
remains a priority and their business is very scalable
=span style="font-size:11.0ptfont-family:"Courier New"">o =hey have 190,000 customers (130,000 of which are
considered very active)
EFTA_R1_02073991
EFTA02702243
o No single merchant accounts for >1% of their revenues=/span>
<=pan style="font-size:11.0pt;font-family:"Courier New"">o H=gh margin business
o High barriers to entry in this market th=t should offer some protection against competition
=OD
o=nbsp; For the fir=t half of 2012, the company processed 169.1M transactions for a total ch=rge volume of $11.3B.
* &n=sp; irayment derives close to 90% of its revenues from the merchant discount fee=it charges to its customers
for services. The fee is based on the size o= the transaction and is typically 2.8% for a credit card transacti=n, with some
variation related to merchant type, card type, and in-person =ersus internet transaction.
=/span>
<=pan style="font-size:11.0pt;font-family:Symbol">. =
Chairman/CEO owns 100% of the company — we like this =s he
thus has a large vested interest to see the business succeed
&n=sp; 7.0x leverage (th=s is fairly high — so the bonds are CCC+ and around a 12.7% yield)=0:p>
We believe 'Payment's bonds offer very attractive =elative value, with the iPayment, Inc. 10.25% notes due 2018
offering = yield of - 12.7%.
Given industry trends, the compa=y's competitive positioning, and these yields, we recommend these bonds=2E
&=bsp;
IPM= 10.25% 05/15/18
<=span>Cusip 46262EAE5
=OD
•
=nbsp; Senior Unsecured<=:p>
* &nb=p;
Rating: B3/CCC+
o This is their only bond (the others are =ay in Kind notes due Nov 2018)
=/span>Please see the JPM Research attached
&=bsp;
2
EFTA_R1_02073992
EFTA02702244
iPayment: Attractive Business with Strong Relative Value; Init=ating with Overweight
We are initiating coverage of iPayment with an Overweight rating. The c=mpany is a leading merchant acquirer serving
small businesses and ha= benefitted from increasing electronic payments by consumers. iPayment h=s generated higher
margins given the challenging nature of the small busin=ss space. While attrition has been a concern, the company
generally uses=excess cash flow to make acquisitions and maintain its portfolio.a:p>
Targets small businesses. iPayment's custome= base consists of small merchants, which typically pay higher
transaction=0D fees than large merchants due to greater business risk, lower volume=, and difficulty in identifying them.
Thus, iPayment can generate better=margins by collecting the higher fees, while still receiving lower process=ng costs by
aggregating small merchant transactions to receive large= volume discounts from their primary payment processor, First
Data.=/o:p>
A=quisitive focus. iPayment has typically used exc=ss cash flow to make acquisitions to grow its portfolio and mitigate
=attrition, which can be meaningful given the higher failure rate in the sm=ll business market. We believe they have
been successful with their acqu=sition strategy, having completed numerous transactions in recent years.=o:p>
Unconventional ownership. Carl Grimstad, iPay=ent's Chairman and CEO, and his affiliations own all of iPayment
Holding=. However, he also has a vested interest in ensuring the success o= the business and is likely to carefully
consider how his potential action= may impact the company and his stake.
Regulatory impact. Since the implementation of the Durbin legislation in Octobe= 2011, margins for processors and
merchant acquirers have benefitted=from lower interchange fee expenses. However, as they continue to pass t=e
savings onto more merchants, merchant discount fees will continue to dec=ine, closing the gap between the top-line
and lower interchange expenses=2E
Industry competition. There are a number o= companies looking to get into the payments business using new
technology=0D including digital wallets, near field communications, and mobile car= readers. However, we believe there
will be little in the way of change =or merchant acquirers such as iPayment in the medium term.
Bottom line. We expect iPayment to contin=e to maintain its top line and generate healthy margins with total l=verage
levels of —7.2x. Although the ownership structure is unconventi=nal, we believe the company has a good management
team, focused on control=ing attrition and growing the portfolio with acquisitions. iPayment's =OA bonds offer very
attractive relative value, with the iPayment, Inc. 1=.25% notes due 2018 offering a yield of 13.34% and the iPayment
Holdin=s 15% PIK notes due 2018 offering a yield of 20.91%. Given industry tr=nds, the company's competitive
positioning, and these yields, we r=commend that investors buy iPayment bonds.
<=p>
This mes=age has been prepared by personnel in one or more affiliates of JPMorgan C=ase & Co. and is not the product
of JPMorgan's Research Department=2E It is not a research report and is not intended as such. =his material is for the
general information of our clients and is a "=olicitation" only as that term is used within CFTC Rule 1.71 and 23=2E605
promulgated under the U.S. Commodity Exchange Act.
=OA
3
EFTA_R1_02073993
EFTA02702245
=OA
Paul Barrett, CFA
Managing Director
Gl=bal Investment Opportunities Group
JPMorgan Private Bank
32= Park Avenue, 14th Floor, New York, NY 10022
NMLS ID# 853441
=OD
=OD
=/span>
&=bsp;
=OA
This email is confidential and subject to important discla=mers and conditions including on offers for the purchase or
sale of securi=ies, accuracy and completeness of information, viruses, confidentiality, l=gal privilege, and legal entity
disclaimers, available at http://www.jpm=rgan.com/pages/disclosures/email.
4
EFTA_R1_02073994
EFTA02702246
Technical Artifacts (5)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Phone
2702243Phone
2702244Phone
2702245Phone
2702246URL
http://www.jpm=rgan.com/pages/disclosures/emailRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.